York Gwill 4

What Happened York Gwill, a director of Alto Neuroscience, was granted a derivative award (an option) to acquire 10,958 shares on May 12, 2026. The reported acquisition price is $0.00 (the award was not purchased), so the immediate cash value reported is $0. This was an award under the company’s director compensation program, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-05-12; Form 4 filed: 2026-05-14 (timely filing).
• Security: derivative/option covering 10,958 shares; reported price $0.00 and Reporting Person paid no consideration (per filing).
• Vesting: Shares underlying the option vest on the earlier of the one-year anniversary of the grant or the issuer’s next annual meeting, subject to continuous service (Footnote F1).
• Source: Issued under the Issuer’s Non-Employee Director Compensation Policy; not sold to the director (Footnote F2).
• Shares owned after transaction: Not disclosed in the filing.

Context This was a compensation award (option grant) to a non-employee director—common corporate practice—rather than a buy or sale signaling a trading view. The option vests over time, which limits immediate disposition. Because the filing reports an award (code A) and not a market purchase or sale, it should be treated as routine director compensation rather than an insider investment signal.